Product Information |
Product name |
Fusidic acid; Fusidine |
CAS No. |
6990-06-3 |
Molecular Formula |
C31H48O6 |
Molecular Weight |
516.719 |
Quality Standard |
97.5% up by HPLC |
Appearance |
White or almost white, crystalline powder |
COA |
ANALYSIS |
SPECIFICATION |
RESULTS |
Appearance |
White or almost white, crystalline powder |
White crystalline powder |
Solubility |
Practically insoluble in water, freely soluble in ethanol (96%) |
Practically insoluble in water, freely soluble in ethanol (96%) |
Identification |
IR: IR absorption spectrum of sample is in identical with that of reference substance |
IR absorption spectrum of sample is in identical with that of reference substance |
Reaction of sodium: The residue does not give reaction (a) of sodium |
The residue does not give reaction (a) of sodium |
|
Water |
1.4%-2.0% |
1.7% |
Sulfated ash |
≤0.2% |
0.1% |
Assay (on anhydrous basis) |
97.5% - 101.0% |
99.9% |
Particle size |
90% Particle diamite < 20 μm |
100% Particle diamite < 20 μm |
Related substance |
Impurity M ≤ 1.0% |
0.1% |
Impurity G ≤ 0.7% |
Not detected |
|
Impurity L ≤ 0.5% |
Not detected |
|
Impurity B ≤ 0.4% |
Not detected |
|
Impurity A ≤ 0.3% |
Not detected |
|
Impurity H ≤ 0.10% |
Not detected |
|
Impurity C ≤ 0.2% |
Not detected |
|
Impurity D ≤ 0.2% |
Not detected |
|
Impurity F ≤ 0.2% |
Not detected |
|
Impurity I ≤ 0.2% |
Not detected |
|
Impurity K ≤ 0.2% |
Not detected |
|
Impurity K ≤ 0.2% |
Not detected |
|
Max unknown impurity ≤ 0.10% |
Not detected |
|
Total impurities ≤ 2.0% |
0.1% |
|
Residual solvents |
Ethanol ≤ 5000pm |
Not detected |
Methanol ≤ 3000pm |
Not detected |
|
Ethyl acetate ≤ 5000pm |
Not detected |
|
N-hexane ≤ 290pm |
Not detected |
|
Microbial limit |
Bacteria ≤ 100cfu/g |
Not detected |
Total molds and yeasts ≤ 10cfu/g |
Not detected |
|
Staphylococcus aureus: None |
Not detected |
|
Pseudomonas aeruginosa: None |
Not detected |
|
Conclusion |
The sample complies with EP. |
Usage |
The application of Fusidic acid:
Fusidic acid is primarily used as an antibiotic to treat bacterial infections. It is commonly applied topically, as a Fusidic acid cream or Fusidic acid ointment, to treat skin infections such as impetigo, infected cuts or wounds, and infected eczema. In some cases, it may also be prescribed orally or intravenously to treat systemic infections, particularly those caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA).
Additionally, fusidic acid has been used in combination with other medications for the treatment of various infections. For example, it may be combined with corticosteroids to treat inflammatory skin conditions or with hydrocortisone to treat otitis externa (outer ear infections).
Fusidic acid works by inhibiting bacterial protein synthesis, specifically targeting the ribosomes within bacterial cells. This mechanism of action makes it effective against a wide range of bacteria, particularly Staphylococcus species. However, it is important to use fusidic acid judiciously to prevent the development of antibiotic resistance.
*Products under the patent are only for R&D use